These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 34510295

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
    Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E.
    Arthritis Res Ther; 2018 Oct 29; 20(1):242. PubMed ID: 30373651
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
    Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC.
    Rheumatol Ther; 2018 Dec 29; 5(2):567-582. PubMed ID: 30414064
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R, Mease PJ, Schwartzman S, Hwang LJ, Soma K, Connell CA, Takiya L, Bananis E.
    Clin Rheumatol; 2017 Jan 29; 36(1):15-24. PubMed ID: 27734232
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.
    Dai Q, Zhang Y, Liu Q, Zhang C.
    Clin Rheumatol; 2024 May 29; 43(5):1605-1613. PubMed ID: 38517652
    [Abstract] [Full Text] [Related]

  • 6. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
    Merola JF, Papp KA, Nash P, Gratacós J, Boehncke WH, Thaçi D, Graham D, Hsu MA, Wang C, Wu J, Young P.
    J Eur Acad Dermatol Venereol; 2020 Dec 29; 34(12):2809-2820. PubMed ID: 32271970
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T, Yamanaka H, Yamaoka K, Arai S, Toyoizumi S, DeMasi R, Fukuma Y, Hirose T, Sugiyama N, Zwillich SH, Tanaka Y.
    Mod Rheumatol; 2019 Sep 29; 29(5):756-766. PubMed ID: 30489177
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
    Mease PJ, Orbai AM, FitzGerald O, Bedaiwi M, Dona L Fleishaker, Mundayat R, Young P, Helliwell PS.
    Arthritis Res Ther; 2023 Aug 22; 25(1):153. PubMed ID: 37608391
    [Abstract] [Full Text] [Related]

  • 9. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS.
    N Engl J Med; 2017 Oct 19; 377(16):1537-1550. PubMed ID: 29045212
    [Abstract] [Full Text] [Related]

  • 10. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.
    Ritchlin CT, Giles JT, Ogdie A, Gomez-Reino JJ, Helliwell P, Young P, Wang C, Wu J, Romero AB, Woolcott J, Stockert L.
    ACR Open Rheumatol; 2020 Oct 19; 2(10):543-554. PubMed ID: 32910531
    [Abstract] [Full Text] [Related]

  • 11. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
    Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, Bushmakin AG, Helliwell PS.
    Arthritis Res Ther; 2022 Feb 09; 24(1):40. PubMed ID: 35139908
    [Abstract] [Full Text] [Related]

  • 12. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS.
    N Engl J Med; 2017 Oct 19; 377(16):1525-1536. PubMed ID: 29045207
    [Abstract] [Full Text] [Related]

  • 13. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
    Nash P, Mease PJ, Fleishaker D, Wu J, Coates LC, Behrens F, Gladman DD, Kivitz AJ, Wei JC, Shirinsky I, Menon S, Romero AB, Fallon L, Hsu MA, Wang C, Kanik KS.
    Lancet Rheumatol; 2021 Jan 19; 3(1):e28-e39. PubMed ID: 38273637
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C, ORAL Step investigators.
    Lancet; 2013 Feb 09; 381(9865):451-60. PubMed ID: 23294500
    [Abstract] [Full Text] [Related]

  • 16. Tofacitinib: A Review in Psoriatic Arthritis.
    Paik J, Deeks ED.
    Drugs; 2019 Apr 09; 79(6):655-663. PubMed ID: 30895473
    [Abstract] [Full Text] [Related]

  • 17. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
    Mulder MLM, Vriezekolk JE, den Broeder N, Mahler EAM, Helliwell PS, van den Hoogen FHJ, den Broeder AA, Wenink MH.
    Trials; 2020 Feb 10; 21(1):155. PubMed ID: 32041657
    [Abstract] [Full Text] [Related]

  • 18. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
    Giles JT, Ogdie A, Gomez Reino JJ, Helliwell P, Germino R, Stockert L, Young P, Joseph W, Mundayat R, Graham D, Ritchlin C.
    RMD Open; 2021 Jan 10; 7(1):. PubMed ID: 33452181
    [Abstract] [Full Text] [Related]

  • 19. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
    Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, FitzGerald O, Fleishaker D, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Romero AB, Kanik KS.
    Rheumatol Ther; 2020 Sep 10; 7(3):553-580. PubMed ID: 32506317
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.